Redeye returns with a more in-depth view on AroCell’s acquisition of IDL Biotech, seeing a new case with more substantial commercial opportunities in the short to medium term, despite TK210 ELISA’s US prospects taking a beating. We reassess our estimates and update our fair value range, which is considerably higher than the current share price. Still, skepticism toward the stock is likely to persist owing to the recent FDA disappointment.